Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase Ib/II trial of anti-CD33 monoclonal antibody BI 836858 and azacitidine in previously untreated older acute myeloid leukemia patients: Beat AML S2 sub-study results.

Haematologica·2026
Same author

Intrinsic cellular resistance to BCR::ABL1 inhibitors.

Haematologica·2026
Same author

Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Blood advances·2026
Same author

The small GTPase ARF6 regulates sphingolipid homeostasis and supports proliferation in acute myeloid leukemia.

Haematologica·2025
Same author

The birth of a paradigm: leukemia-initiating cells in acute myeloid leukemia.

Haematologica·2025
Same author

Molecular characterization of newly diagnosed acute myeloid leukemia patients aged 60 years or older: a report from the Beat AML clinical trial.

Blood cancer journal·2025

Related Experiment Video

Updated: May 13, 2026

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

Molecular diagnostics in chronic myeloid leukemia.

Thoralf Lange1, Michael W Deininger

  • 1Abteilung für Hämatologie, Onkologie und Hämostaseologie, Universitätsklinikum Leipzig, Germany.

Expert Opinion on Medical Diagnostics
|March 15, 2013
PubMed
Summary

Sophisticated molecular tools aid chronic myeloid leukemia (CML) diagnosis and monitoring. This review clarifies standard and emerging diagnostic methods, including BCR-ABL1 testing, for effective CML patient management.

More Related Videos

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Related Experiment Videos

Last Updated: May 13, 2026

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients
13:21

Comprehensive DNA Methylation Analysis Using a Methyl-CpG-binding Domain Capture-based Method in Chronic Lymphocytic Leukemia Patients

Published on: June 16, 2017

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Area of Science:

  • Hematology
  • Molecular Diagnostics
  • Oncology

Background:

  • Chronic myeloid leukemia (CML) therapy has advanced, necessitating sophisticated diagnostic and monitoring tools.
  • Standard diagnostic procedures include physical examination, complete blood count, and bone marrow biopsy with metaphase karyotyping.
  • Molecular assays like fluorescence in situ hybridization and polymerase chain reaction are crucial for specific CML diagnoses.

Purpose of the Study:

  • To review universally accepted and controversial diagnostic and monitoring methods for CML.
  • To provide an update on emerging technologies in CML diagnostics.
  • To guide the rational and economic use of the CML diagnostic armamentarium.

Main Methods:

  • Review of current diagnostic standards and molecular techniques for CML.
  • Discussion of fluorescence in situ hybridization, qualitative and quantitative reverse transcription polymerase chain reaction (qPCR) for BCR-ABL1.
  • Analysis of BCR-ABL1 kinase domain mutation screening and qPCR result interpretation.

Main Results:

  • Bone marrow karyotyping is standard for initial CML monitoring until complete cytogenetic response.
  • Quantitative PCR for BCR-ABL1 becomes the preferred method post-cytogenetic response, requiring careful interpretation.
  • BCR-ABL1 mutation screening aids in managing imatinib resistance.

Conclusions:

  • Integrating various CML diagnostic tools requires a strategic approach.
  • Standardization of qPCR results on an international scale improves comparability.
  • Emerging technologies offer potential advancements in CML diagnostics and patient management.